Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
February 28, 2026

Blujepa / gepotidacin for treating uncomplicated urinary tract infections as of February 2026

MARA Rating Company February 28, 2026

Inluriyo / imlunestrant for eSR1-Mutated Advanced or Metastatic Breast Cancer After Endocrine Therapy as of February 2026

MARA Rating Company February 28, 2026

Doxecitine plus doxribtimine (kygevvi) for tK2 Deficiency as of February 2026

MARA Rating Company February 28, 2026

Lerochol / lerodalcibep-liga for lDL-C Reduction in adults with hypercholesterolemia, including HeFH as of February 2026

MARA Rating Company February 28, 2026

Vizz / aceclidine for presbyopia as of February 2026

MARA Rating Company February 28, 2026

Tryptyr / acoltremon for treatment of dry eye disease as of February 2026

MARA Rating Company February 28, 2026

Asundexian for secondary prevention after non-cardioembolic ischemic stroke or high-risk transient ischemic attack as of February 2026

MARA Rating Company February 28, 2026

Vanrafia / atrasentan for reducing proteinuria in primary IgA nephropathy as of February 2026

MARA Rating Company February 28, 2026

Avutometinib plus dafacitinib for kRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer as of February 2026

MARA Rating Company February 28, 2026

Cagrilintide and semaglutide (cagrisema) for treating Obesity and Overweight With Obesity-Related Comorbidities as of February 2026

MARA Rating Company February 28, 2026